Poor Mid-Stage Results Sink AbbVie’s Plans for Cancer Drug By Sam | March 21, 2018 After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug. Source: BioSpace Posted in BioPharma